Guided Therapeutics (GTHP) Total Liabilities (2010 - 2025)

Guided Therapeutics' Total Liabilities history runs 16 years deep, the most recent figure standing at $7.3 million for Q4 2025.

• In Q4 2025, Total Liabilities rose 16.96% year-over-year to $7.3 million; the TTM figure through Dec 2025 stood at $7.3 million (up 16.96% YoY), while the FY2025 annual figure was $7.3 million, up 16.96% from the prior year.
• Total Liabilities came in at $7.3 million for Q4 2025 at Guided Therapeutics, up from $6.5 million in the prior quarter.
• In the past five years, Total Liabilities ranged from a high of $10.3 million in Q1 2021 to a low of $5.5 million in Q4 2023.
• A 5-year average of $6.6 million and a median of $6.3 million in 2024 frame the typical range for Total Liabilities.
• Across the five-year window, Total Liabilities plunged 57.44% in 2021 and increased 16.96% in 2025, its largest moves.
• Guided Therapeutics' Total Liabilities stood at $7.5 million in 2021, then retreated by 16.51% to $6.2 million in 2022, then fell by 12.39% to $5.5 million in 2023, then advanced by 14.47% to $6.3 million in 2024, then rose by 16.96% to $7.3 million in 2025.
• According to Business Quant data, Total Liabilities over the past three periods registered $7.3 million, $6.5 million, and $6.4 million for Q4 2025, Q3 2025, and Q2 2025 respectively.

Peer Comparison